Marion Peters, M.D.
Dr. Peters is a Professor of Medicine and Chief of Hepatology Research at the University of California at San Francisco, where she currently holds the John V. Carbone, MD, Endowed Chair in Medicine. She received her Bachelor of Medicine/Bachelor of Surgery degree and her Doctorate of Medicine from Melbourne University Medical School in Melbourne, Australia. She is a hepatologist with a particular interest in viral hepatitis and autoimmune liver diseases. She was trained in clinical and translational research at NIH (A.S. Fauci; J.H. Hoofnagle) and the Walter and Eliza Hall Institute of Medical Research.
Her research focuses on viral hepatitis in complicated clinical settings, patients with co-morbid conditions including alcoholism and HIV infection. In these complex situations she focuses on the role of host responses to hepatitis virus infection, and examine the effect of alcohol, cannabis and HIV on the progression of viral hepatitis and the response to anti-viral therapy. Her group has studied the role of noninvasive markers of fibrosis on outcome of liver disease in HIV-HCV co-infected individuals in a large multicenter NIH funded study, the Women’s Interagency HIV study (WIHS). She is interested in progression of fibrosis in patients with viral hepatitis, with and without HIV and is studying new serum markers to evaluate liver fibrosis. She is Liver co-chair of the NIH funded Women’s Interagency HIV study (WIHS) Hepatitis Group. She has numerous publications on viral hepatitis with and without HIV coinfection in peer-reviewed journals with multiple collaborations.
Dr. Peters was initially funded by an ALF Liver Scholar award. She has studied the role race/ethnicity on diagnosis of primary biliary cholangitis. She is investigating the effect of age on presentation of autoimmune liver disease and the factors affecting recurrence of autoimmune liver diseases after liver transplantation.
She led the NIH AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group (TSG) for 4 years where she championed young investigators to be chairs of new trials in Hep TSG. In the ACTG, she was the driving force in the development of US and international studies of new all oral direct acting antiviral HCV drugs for patients with HCV, with and without HIV. She has created an international group of hepatitis experts to studies new therapies for HBV cure both in US and internationally. She is currently a team member or co-chair of 3 ACTG hepatitis trials. She is also a member of the HEP TSG steering committee.
She teaches medical students, housestaff and fellows at UCSF. She has trained fellows, housestaff and medical students in clinical and translational research, many of whom have gone on to faculty positions focusing on liver disease. She is co-director of the Hepatology training grant (T32) at UCSF and a member of the UCSF Liver Center.
Peter Cullen is an entrepreneur, angel investor, and media consultant/executive, who served in senior leadership and strategy roles with both major entertainment and start-up companies.
Peter began his career with The Walt Disney Company where he quickly rose through the ranks achieving the role of Vice President and head of business development for Disney/ABC Media Networks. As the Internet marketplace emerged, Peter left Disney to become Vice President of Business Development for America Online, leading West Coast Operations; and Executive Vice President of Business Development for Liberty Media’s ACTV, Inc.
Joining start-up Premier Retail Networks (PRN) and leading their business development and media partnerships, Peter helped build PRN to a $285M acquisition by Thomson SA. Peter then founded Wovenmedia, an innovator in cloud based video management and publishing, which currently reaches over 43 million monthly viewers in over 28,000 locations.
Peter holds two B.A. degrees from the University of California at Los Angeles, and an M.B.A. from Loyola Marymount University.
Peter continues to thrive personally and professionally despite being diagnosed with Ulcerative Colitis at age 15 and Primary Sclerosing Cholangitis at age 35. He is a survivor of stage three colon cancer and cholangiocarcinoma, the recipient of two liver transplants, and has relied on over thirty endoscopic and percutaneous procedures to restore his health. He currently serves on the Board of the American Liver Foundation’s Northern California and Nevada Division.
Mr. Eddie Gray joined Dynavax as Chief Executive Officer and was appointed to our Board in May 2013. Most recently, Mr. Gray served as the President of Pharmaceuticals Europe and a member of the corporate executive team at GlaxoSmithKline plc (GSK) since 2008 and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. Prior to the formation of GSK, Mr. Gray was with SmithKline Beecham from 1988 through 2000 serving in various positions of increasing responsibility, including Vice President and Director of Anti-Infectives Marketing in the US, Vice President and Director of the Vaccines Business Unit in the US, and Vice President and General Manager of
Pharmaceuticals in Canada. Mr. Gray received a Bachelor of Science degree in Chemistry and Management Studies from the University of London and an MBA from the Cranfield School of Management in the UK.